Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Joni Rutter, director of the National Center for Advancing Translational Sciences (NCATS), discusses the centre’s audacious goal to have 25% of diseases covered by the experimental drug pipeline by 2032.
Joni Rutter has been working at the intersection between genomics and disease at the NIH for over two decades — with stints at the National Cancer Institute, the National Institute on Drug Abuse and the All of Us precision medicine programme. When a position opened up for deputy director at NCATS in 2019, she grabbed the chance to push her learnings into practice, focusing on accelerating the translation of research findings into therapeutics.